A new BRAF inhibitor breaks resistance barriers.
BRAF
CRAF
RAF1
dimerization
paradoxical effect
resistance
Journal
Trends in cancer
ISSN: 2405-8025
Titre abrégé: Trends Cancer
Pays: United States
ID NLM: 101665956
Informations de publication
Date de publication:
11 Jun 2024
11 Jun 2024
Historique:
received:
24
05
2024
revised:
29
05
2024
accepted:
30
05
2024
medline:
13
6
2024
pubmed:
13
6
2024
entrez:
12
6
2024
Statut:
aheadofprint
Résumé
Approved BRAF inhibitors have shown limited clinical benefit due to recurrent disease progression. In a recent Cancer Discovery paper, Yaeger et al. show that a next-generation BRAF inhibitor, PF-07799933, has widespread therapeutic activity in experimental models and patients who were refractory to treatment with approved BRAF inhibitors.
Identifiants
pubmed: 38866669
pii: S2405-8033(24)00111-0
doi: 10.1016/j.trecan.2024.05.009
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors have no interests to declare.